(E)-3-(4-(3-(4-isopropylpiperazin-1-yl)prop-1-en-1-yl)benzyl)-2,5,7-trimethyl-3H-imidazo[4,5-b]pyridine

ID: ALA4060989

PubChem CID: 57970240

Max Phase: Preclinical

Molecular Formula: C26H35N5

Molecular Weight: 417.60

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1cc(C)c2nc(C)n(Cc3ccc(/C=C/CN4CCN(C(C)C)CC4)cc3)c2n1

Standard InChI:  InChI=1S/C26H35N5/c1-19(2)30-15-13-29(14-16-30)12-6-7-23-8-10-24(11-9-23)18-31-22(5)28-25-20(3)17-21(4)27-26(25)31/h6-11,17,19H,12-16,18H2,1-5H3/b7-6+

Standard InChI Key:  CLHMXDLUVJPYFO-VOTSOKGWSA-N

Molfile:  

     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   28.8448  -11.6467    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.5554  -11.2360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2644  -11.6425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2646  -12.4612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.9769  -12.8717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6885  -12.4568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6834  -11.6313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.9706  -11.2286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3999  -12.8629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1056  -12.4507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8153  -12.8558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5210  -12.4436    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.2301  -12.8516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9337  -12.4430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9338  -11.6254    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.2242  -11.2182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5144  -11.6285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.6410  -11.2160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.3492  -11.6237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.6400  -10.3988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.0970  -11.3188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.5481  -11.9290    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.7615  -12.4685    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9619  -12.6354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.7082  -13.4099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.2530  -14.0181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0548  -13.8467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3048  -13.0725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.9247  -10.5200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9084  -13.5778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6026  -14.4532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  3  1  0
  6  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 12 17  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 15 18  1  0
 18 19  1  0
 18 20  1  0
  1 21  1  0
 21 22  2  0
 22 24  1  0
 23  1  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 23  1  0
 21 29  1  0
 25 30  1  0
 27 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4060989

   2,5,7-trimethyl-3-[[4-[(E)-3-(4-propan-2-ylpiperazin-1-yl)prop-1-enyl]phenyl]methyl]imidazo[4,5-b]pyridine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 417.60

Molecular Weight (Monoisotopic): 417.2892

AlogP: 4.44

#Rotatable Bonds: 6

Polar Surface Area: 37.19

Molecular Species: BASE

HBA: 5

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.51

CX LogP: 4.30

CX LogD: 3.16

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.59

Np Likeness Score: -1.43

References

1. Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D, Nash M, Loetscher P..  (2017)  Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis.,  25  (16): [PMID:28689977] [10.1016/j.bmc.2017.06.050]

Source

Source(1):

• Scientific Literature